Please assess the completion status of the following clinical trial:

Trial Title: Panama and El Salvador Children's Oseltamivir Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<10 years~* Accompanied by a parent or guardian who has the capacity to grant and sign the written informed consent and who has consented to enrollment~* Has respiratory illness as defined by modified IMCI criteria for pneumonia:~* Cough or sore throat AND Fast breathing, defined as respiratory rate 60 breaths per minutes or greater for children 0 to \<2 months, OR respiratory rate 50 breaths per minute or greater for children 2 to \<12 months, OR respiratory rate 40 breaths per minute or greater for children 12 to \<60 months, OR respiratory rate 30 breaths per minute or greater for children 5-9 years~* Planned for hospital admission~Exclusion Criteria:~* Symptom onset 7 days or more at the time of study screening where day 1 is the day of symptom onset~* Concomitant severe vomiting illness prior to enrollment that would preclude ability to take medication orally defined as more than 3 vomiting episodes in the preceding 24 hours~* Prematurity (birth at less than 37 weeks gestation) for children aged less than 3 months~* Birth weight less than 2500 grams for children aged less than 3 months~* Chronic supplemental oxygen requirement at home~* Known history of renal dysfunction~* History of gastrointestinal resection resulting in gastrointestinal abnormality that might hinder absorption of oral medication (such as short-gut syndrome)~* History of previous serious adverse reaction to oseltamivir phosphate~* Receipt of oseltamivir phosphate during the 5 days prior to presentation at the admitting hospital~* Previous enrollment in this study during a hospitalization that ended less than 14 days prior to the current admission

- Gender: ALL
- Minimum Age: None
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Oseltamivir phosphate suspension (Type: ACTIVE_COMPARATOR): Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).